Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
3 Months Ended
Mar. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events

Note 11 – Subsequent Events


On April 2, 2019, the Company agreed to provide funds in the amount of $157,405 per year under a Cooperative Research and Development Agreement (“ CRADA”) to support the National Institute of Allergy and Infectious Diseases investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of encochleated drug products in patients with fungal, bacterial, or viral infections. The term of the CRADA is three years.